What is she best known for?
The fields of study she is best known for:
- Virus
- Antibody
- Immune system
Her scientific interests lie mostly in Virology, Antibody, Immunization, Immunology and Vaccination.
Her biological study spans a wide range of topics, including Epitope, Monoclonal antibody and Immunogenicity.
Her Monoclonal antibody research integrates issues from Virus and Neutralization.
Her study in Antibody focuses on Neutralizing antibody in particular.
Her Immunization research incorporates themes from Plasmodium falciparum, Malaria, Viral load, Severe acute respiratory syndrome coronavirus 2 and PfSPZ vaccine.
Her work on Immunology is being expanded to include thematically relevant topics such as Clinical trial.
Her most cited work include:
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (874 citations)
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. (803 citations)
- Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine (517 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Virology, Antibody, Immunology, Vaccination and Clinical trial.
Her Virology research focuses on Virus in particular.
Her Antibody course of study focuses on Severe acute respiratory syndrome coronavirus 2 and 2019-20 coronavirus outbreak, Messenger RNA and Pneumonia.
Her Immunology study often links to related topics such as HIV vaccine.
Her Vaccination study incorporates themes from Heterologous and Immune system.
In her study, Pharmacokinetics and Acquired immunodeficiency syndrome is inextricably linked to Adverse effect, which falls within the broad field of Clinical trial.
She most often published in these fields:
- Virology (62.16%)
- Antibody (44.14%)
- Immunology (39.64%)
What were the highlights of her more recent work (between 2019-2021)?
- Antibody (44.14%)
- Neutralization (19.82%)
- Virology (62.16%)
In recent papers she was focusing on the following fields of study:
Antibody, Neutralization, Virology, Severe acute respiratory syndrome coronavirus 2 and Pharmacokinetics are her primary areas of study.
Antibody is a subfield of Immunology that Julie E. Ledgerwood studies.
Her work deals with themes such as Hemagglutinin, Titer and Immunity, which intersect with Neutralization.
Her study focuses on the intersection of Virology and fields such as Pandemic with connections in the field of Influenza A virus.
Her study on Severe acute respiratory syndrome coronavirus 2 also encompasses disciplines like
- 2019-20 coronavirus outbreak which intersects with area such as Immunogenicity,
- Immunization and related Pneumonia.
Julie E. Ledgerwood interconnects Bioavailability, Clinical trial, Phases of clinical research and Physiology in the investigation of issues within Pharmacokinetics.
Between 2019 and 2021, her most popular works were:
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (874 citations)
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. (803 citations)
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. (292 citations)
In her most recent research, the most cited papers focused on:
- Virus
- Antibody
- Immune system
Her main research concerns Severe acute respiratory syndrome coronavirus 2, Antibody, 2019-20 coronavirus outbreak, Vaccination and Messenger RNA.
The study incorporates disciplines such as Immunization and Virology in addition to Severe acute respiratory syndrome coronavirus 2.
Her Immunization study which covers Pneumonia that intersects with Viral replication, Betacoronavirus, Pandemic and Viral Vaccine.
Her Antibody study improves the overall literature in Immunology.
Her Vaccination study integrates concerns from other disciplines, such as Tolerability, Adverse effect, Randomized controlled trial and Reactogenicity.
Her Coronavirus research is multidisciplinary, relying on both Incidence, Young adult, Placebo, Clinical endpoint and Vaccine efficacy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
